Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea

Sleep

Volumn 31, Issue 6, 2008, Pages 824-831

  Marshall, Nathaniel S ^a   Yee, Brendon J ^a   Desai, Anup V ^a   Buchanan, Peter R ^a   Wong, Keith K H ^a   Crompton, Renee ^a   Melehan, Kerri L ^a   Zack, Nadene ^b   Rao, Srinivas G ^b   Gendreau, R Michael ^b   Kranzler, Jay ^b   Grunstein, Ronald R ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Cypress Bioscience Inc   (United States)

^c WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Apnea; Clinical trial; Drug treatment; Mirtazapine; Placebo controlled; Randomized; Serotonin

Indexed keywords

AVANZA; CD 0012; CD 0013; DRUG; MIRTAZAPINE; PLACEBO;

ADULT; ANALYTIC METHOD; ARTICLE; BEDTIME DOSAGE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; LETHARGY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP APNEA SYNDROME; WEIGHT GAIN;

EID: 44949217822     PISSN: 01618105     EISSN: None     Source Type: Journal    
DOI: 10.1093/sleep/31.6.824     Document Type: Article

References (43)

1. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-39.
2. Peppard P, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. New Eng J Med 2000;342:1378-84.
3. Peppard PE, Szklo-Coxe M, Hla KM, et al. Longitudinal association of sleep-related breathing disorder and depression. Arch Intern Med 2006;166:1709-15.
4. Lavie P, Herer P, Peled R, et al. Mortality in sleep apnea patients - a multivariate analysis of risk factors. Sleep 1995;18:149-57.
5. Marti S, Sampol G, Munoz X, et al. Mortality in severe sleep apnoea/hypopnoea syndrome patients: impact of treatment. Eur Respir J 2002;20:1511-8.
6. Marin J, Carrizo S, Vincente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005;365:1046-53.
7. Giles T, Lasserson T, Smith B, et al. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006;19 July 2006.
8. Patel S, White D, Malhotra A, et al. Continuous positive airway pressure therapy for treating sleepiness in a diverse population with obstructive sleep apnea: results of a meta-analysis. Arch Intern Med 2003;163:565-71.
9. Marshall NS, Barnes M, Travier N, et al. Continuous positive airway pressure reduces daytime sleepiness in mild to moderate obstructive sleep apnoea: a meta-analysis. Thorax 2006;61:430-4.
10. Lim J, Lasserson T, Fleetham J, et al. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev 2006;1:CD004435.
11. Sundaram S, Bridgman S, Lim J, et al. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev 2005;4:CD001004.
12. Smith I, Lasserson T, Wright J. Drug therapy for obstructive sleep apnoea in adults. Cochrane Database Syst Rev 2006;2:CD003002.
13. Strollo P, Jr, Atwood C, Jr, Sanders M. Medical therapy for obstructive sleep apnea-hypopnea syndrome. In: Kryger MH, Roth T, Dement WC, eds. Principles and Practice of Sleep Medicine, 4th ed., Philadelphia: Elsevier/Saunders; 2005:1053-65.
14. Whyte K, Gould G, Airlie M, et al. Role of protriptyline and acetazolomide in the sleep apnea/hypopnea syndrome. Sleep 1988;11:463-72.
15. Yee B, Phillips C, Banerjee D, et al. The effect of sibutramine-assisted weight loss in men with obstructive sleep apnoea. Int J Obes (Lond) 2007;31:161-8.
16. Carley D, Olopade C, Ruigt G, et al. Efficacy of mirtazapine in obstructive sleep apnea syndrome. Sleep 2007;30:35-41.
17. Johns MW. Sleepiness in different situations measured by the Epworth sleepiness scale. Sleep 1994;17:703-10.
18. Rechtschaffen A, Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Los Angeles: Brain Information Service/ Brain Research Institute University of California; 1968
19. EEG arousals: scoring rules and examples: a preliminary report from the Sleep Disorders Atlas Task Force of the American Sleep Disorders Association. Sleep 1992;15:173-84.
20. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The report of an American Academy of Sleep Medicine Taskforce. Sleep 1999;22:667-89.
21. Brown H, Prescott R, Applied mixed models in medicine., Chichester: John Wiley and Sons; 1999:408.
22. Kazis L, Anderson J, Meenan R. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-S89.
23. Castillo J, Menendez P, Segovia L, et al. Effectiveness of mirtazapine in the treatment of sleep apnea/hypopnea syndrome (SAHS). Sleep Med 2004;5:507-8.
24. Carley DW, Radulovacki M. Mirtazapine, a mixed-profile serotonin agonist/antagonist, suppresses sleep apnea in the rat. Am J Respir Crit Care Med 1999;160:1824-9.
25. Biswas P, Wilton L, Shakir S. The pharmacovigilance of mirtazapine: results of a prescription event monitoring study on 13 555 patients in England. J Psychopharmacology 2003;17:121-6.
26. Young T, Peppard PE, Taheri S. Excess weight and sleep-disordered breathing. J Appl Physiol 2005;99:1592-9.
27. de Boer T, Maura G, Raiteri M, et al. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, org 3770 and its enantiomers. Neuropharmacology 1988;27:399-408.
28. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacol 1997;17:2S-18S.
29. Ruigt G, Kemp B, Groenhout C, et al. Effect of the antidepressant org 3770 on human sleep. Eur J Clin Pharmacol 1990;38:551-4.
30. Bayliss D, Viana F, Talley E, et al. Neuromodulation of hypoglossal motoneurons: cellular and developmental mechanisms. Respir Physiol 1997 110:139-50.
31. Berger A, Bayliss D, Viana F. Modulation of neonatal rat hypoglossal motoneuron excitability by serotonin. Neurosci Lett 1992;143:164-8.
32. Douse M, White D. Serotonergic effects on hypoglossal neural activity and reflex responses. Brain Res 1996;726:213-22.
33. Kubin L, Tojima H, Davies R, et al. Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat. Neurosci Lett 1992;139:243-8.
34. Ribeiro-do-Valle L, Metzler C, Jacobs B. Facilitation of masseter EMG and masseteric (jaw-closure) reflex by serotonin in behaving cats. Brain Res 1991;550:197-204.
35. Veasey S, Fornal C, Metzler C, et al. Response of serotonergic caudal raphe neurons in relation to specific motor activities in freely moving cats. J Neurosci 1995;15:5346-59.
36. Veasey S, Panckeri K, Hoffman E, et al. The effects of serotonin antagonists in an animal model of sleep disordered breathing. Am J Respir Crit Care Med 1996;153:776-86.
37. Berry R, Koch G, Hayward L. Low-dose mirtazapine increases genioglossus activity in the anesthetized rat. Sleep 2005;28:78-84.
38. Thase M. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999;60:28-31.
39. Carley D, Olopade C, Seink S, et al. Serotonin antagonist improves obstructive sleep apnea. Sleep Med 2003;4:S6.
40. Kasper S, Praschak-Rieder N, Tauscher J, et al. A risk-benefit assessment of mirtazapine in the treatment of depression. Drug Saf 1997;17:251-64.
41. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep disordered breathing. JAMA 2000;284:3015-21.
42. Cistulli P, Grunstein R. Medical devices for the diagnosis and treatment of obstructive sleep apnea. Expert Rev Med Devices 2005;2:749-63.
43. Hedner J, Kraiczi H, Peker Y, et al. Reduction of sleep-disordered breathing after physostigmine. Am J Respir Crit Care Med 2003;168:1246-51.